Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Allogeneic, Autologous, BCMA, CAR-T

April 16, 2020

J&J Q1 2020 Earnings Update

Here is a brief preview of this blast: On Tuesday, April 14, J&J held their Q1 ‘20 earnings call (press release / slides). While the call focused predominantly on J&J's response to the COVID-19 crisis, the company stated that filing of JNJ-4528 (BCMA CAR-T) continues to be projected for H2 2020. J&J also emphasized their determination to reduce the impact of the pandemic on their ongoing clinical trials. Below, FENIX provides highlights and analysis from the call, including how JNJ-4528's upcoming filing may impact BMS's ide-cel, the current BCMA CAR-T frontrunner.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.